A qualified tool does not eliminate regulatory scrutiny. It eliminates the need to keep proving that the same ruler works.
What if one of the biggest sources of friction in medical device development is not the device itself—but the tool being used to measure its performance?
Historically, FDA evaluated many of these tools as part of individual device submissions. The Medical Device Development Tools (MDDT) program creates a different pathway: qualify a tool for a defined context of use, and sponsors can rely on that qualification in subsequent device development and regulatory submissions without having to repeatedly establish the tool’s suitability for that same use.
This Deep Dive explores what that means for evidence generation, regulatory strategy, and medical device development.
Key highlights covered in the audio:
* Why MDDT exists: reducing repeated evaluation of the same measurement and assessment methods across device submissions.
* Context of use is everything: qualification applies only within clearly defined boundaries for how, where, and for what purpose the tool is used.
* Different forms of evidence: qualified tools can include clinical outcome assessments, biomarker tests, non-clinical assessment models, and other specialized tools.
* From patient-reported outcomes to computational models: examples show how FDA is qualifying increasingly diverse ways of generating evidence.
* A more predictable development strategy: the MDDT process allows developers to establish the scientific credibility of a tool before relying on it in future regulatory decisions.
The important point is that MDDT qualification does not replace evaluation of the medical device itself.
Instead, it can reduce uncertainty around something equally important: whether the method being used to generate the evidence is scientifically credible for its intended purpose.
Keywords:
FDA MDDT, Medical Device Development Tools, Context of Use, Regulatory Science, Clinical Outcome Assessments, Biomarker Tests, Non-Clinical Assessment Models, Computational Modeling, Evidence Generation, Medical Device Development
🎧Listen to the Deep Dive for a closer look at how FDA’s MDDT program can reduce repeated validation work, improve predictability, and change how medical device teams think about evidence-generation strategy.
Thanks for reading Let's Talk Risk!. If you liked this post, share with others.
Note:
The audio summary was prepared using Google NotebookLM, an AI-enabled research tool. Here are a few key resources used for this analysis:
* FDA (2026). Medical Device Development Tools (MDDT) Program Guidance & Qualified Tools Registry (CDRH-FD&C Act Section 507).
* FDA (2024). Summary of Evidence and Basis of Qualification (SEBQ) for Apple Atrial Fibrillation History Feature.Apple AFib History Feature SEBQ Document (PDF)
* FDA (2024). Premarket Approval Application (PMA) Review for Abbott Medical’s TriClip G4 System. FDA Advisory Committee Review Presentation (PDF)
* FDA (2020). CDRH Qualification of the Kansas City Cardiomyopathy Questionnaire (KCCQ) as a Clinical Outcome Assessment Instrument.Listed in the FDA MDDT Qualified Tools Registry
* FDA (2026). Qualification of MolecuLightDX Wound Measurement as a Medical Device Development Tool. MolecuLightDX MDDT Qualification Announcement
This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe
